Definium Therapeutics, Inc. Common Shares (DFTX)
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
- Headquarters
- United States
- Employees
- 106
- Market Cap
- $5.7B
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
SentiSense also tracks daily options readings for Definium Therapeutics, Inc. Common Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Definium Therapeutics, Inc. Common Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.